Sign In
Buy OKYO
$1.66
-0.0400 (-2.35%)
At Close: Jun 03, 2026
OKYO Pharma insiders acquire shares
09:25am, Friday, 31'st Jan 2025
OKYO Pharma Ltd (NASDAQ:OKYO) announced that its chief executive officer Gary Jacob has purchased 10,000 of the company's shares at US$1.04 per share. Additionally, Panetta Partners, in which executi
OKYO Pharma Announces Chairman and CEO Acquire Shares
07:00am, Friday, 31'st Jan 2025
LONDON and NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic c
Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited
09:45am, Thursday, 30'th Jan 2025
BALTIMORE, MD / ACCESS Newswire / January 30, 2025 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published
OKYO Pharma nears full enrollment for neuropathic corneal pain trial with results expected by year-end
10:10am, Wednesday, 29'th Jan 2025
OKYO Pharma Ltd (NASDAQ:OKYO) has provided an update on its clinical programs along with the release of interim financial results for the six months ending in September 2024. The company said it expe
OKYO Pharma secures non-dilutive funding to advance clinical programs
08:46am, Wednesday, 22'nd Jan 2025
OKYO Pharma Ltd (NASDAQ:OKYO) has announced the receipt of $1.4 million in non-dilutive funding. The clinical-stage biopharmaceutical company is developing novel therapies for neuropathic corneal pain
MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
09:00am, Friday, 15'th Nov 2024
ORLANDO, FL / ACCESSWIRE / November 15, 2024 / RedChip Companies will air interviews with MUSQ Global Music Industry ETF (NYSE:MUSQ) and OKYO Pharma Ltd. (Nasdaq:OKYO) on the RedChip Small Stocks, Big
OKYO Pharma to present Phase 2 dry eye disease trial data at TFOS conference
09:38am, Wednesday, 30'th Oct 2024
OKYO Pharma Ltd (NASDAQ:OKYO) announced it will present at the 10th International Tear Film & Ocular Surface Society (TFOS) Conference in Venice, Italy, being held from October 30 to November 2, 2024
OKYO Pharma doses first patient in Phase 2 neuropathic corneal pain trial - ICYMI
10:22am, Saturday, 26'th Oct 2024
OKYO Pharma Ltd (NASDAQ:OKYO) CEO Gary Jacob joined Proactive to discuss recent developments in the company's Phase 2 clinical trial for OK-101, an investigational therapy targeting neuropathic cornea
OKYO Pharma doses first patient in Phase 2 neuropathic corneal pain trial
09:40am, Wednesday, 23'rd Oct 2024
OKYO Pharma Ltd (NASDAQ:OKYO) announced that the first patient has been dosed in the Phase 2 trial of its investigational therapeutic topical OK-101 to treat neuropathic corneal pain (NCP). NCP, which
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain
07:00am, Wednesday, 23'rd Oct 2024
LONDON and NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat corneal neuropathic p
OKYO Pharma begins Phase 2 trial for neuropathic corneal pain treatment
09:26am, Wednesday, 16'th Oct 2024
OKYO Pharma Ltd (NASDAQ:OKYO) has started recruiting patients for its Phase 2 trial of its ocular therapy OK-101, aimed at treating neuropathic corneal pain (NCP). The trial comes as part of OKYO's br
OKYO Pharma secures key US patent for dry eye disease therapy
08:43am, Tuesday, 27'th Aug 2024
OKYO Pharma Ltd (NASDAQ:OKYO) announced it has been granted a US patent covering claims on its investigational therapeutic OK-101's use to treat irritated, burning eyes and blurred vision in patients
OKYO Pharma CEO Interview to Air on Bloomberg TV
09:00am, Friday, 23'rd Aug 2024
LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflam
OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
09:00am, Friday, 23'rd Aug 2024
ORLANDO, FL / ACCESSWIRE / August 23, 2024 / RedChip Companies will air interviews with OKYO Pharma Ltd. (Nasdaq:OKYO) and SolarMax Technology, Inc. (Nasdaq:SMXT) on the RedChip Small Stocks, Big Mone
OKYO Pharma Announces Chairman Acquires Shares
07:00am, Friday, 23'rd Aug 2024
LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflam
